Jibeier Pharmaceutical: The investigational anti-tumor new drug injectable JJH201601 liposome has obtained approval for clinical trials
Jibeier Pharmaceutical recently announced that its investigational anti-tumor new drug injectable JJH201601 liposome has received clinical trial approval from the National Medical Products Administration. The drug will be used in clinical trials in combination with cetuximab and/or toripalimab for advanced head and neck squamous cell carcinoma. JJH201601 liposome is a novel compound developed based on a liposome drug development technology platform
According to the announcement from Jibeier Pharmaceutical (688566.SH), the company has recently received the "Notice of Approval for Drug Clinical Trials" issued by the National Medical Products Administration. The clinical trial application for the company's investigational anti-tumor new drug, injectable JJH201601 liposome, meets the relevant requirements for drug registration and is approved to conduct clinical trials in advanced head and neck squamous cell carcinoma in combination with cetuximab (β) and/or toripalimab.
Injectable JJH201601 liposome is an anti-tumor new drug developed by the company based on its liposome drug research and development technology platform. Through molecular design and pharmacodynamic testing, a new compound has been obtained, which is developed into a liposome formulation using liposome technology
